Natera (NTRA) Insider Eric Rubin Buys 75 Shares

Insider Buying and Selling at Natera, Inc.

Eric Rubin acquired 75 shares of Natera, Inc. (NasdaqGS: NTRA) on June 26, 2026. While modest in size compared to some multi-thousand share transactions reported that same day, the purchase adds to a broader cluster of buying activity among company insiders.

More Insider Activity at Natera

That same day on June 26, 2026, several other insiders added to their holdings. Rowan Chapman acquired 1,674 shares, Thomas Lynch JR. picked up 1,905 shares, Roelof Botha bought 1,691 shares, and Roy Baynes purchased 1,646 shares. These purchases followed earlier sales in late June, including a planned sale of 33,600 shares by Secretary and Chief Legal Officer Daniel Rabinowitz on June 24, 2026, at an average price of $251.65 for a total of $8,455,403.04, and a sale of 16,530 shares by Herm Rosenman at $250.00 per share totaling $4,132,500.00.

Natera Stock and Market Standing

Natera shares trade on the NasdaqGS under the ticker NTRA. The stock has experienced wide swings over the past year, trading as low as $157.43 and reaching a high of $373.07. With a market value exceeding $53 billion, the diagnostics provider operates with a beta of 1.53, reflecting higher volatility than the broader market.

Wall Street Analyst Views

Major financial firms continue to adjust their outlooks on Natera. On October 14, 2026, JP Morgan maintained its Overweight rating while lifting its price target from $360.00 to $460.00. Morgan Stanley kept an Overweight rating on October 13, 2026, moving its target to $435.00 from $355.00. On the same day, TD Cowen maintained a Buy rating and raised its target to $480.00 from $340.00. Barclays followed suit on October 7, 2026, keeping an Overweight rating with a $475.00 target. Citigroup maintained a Buy rating on October 6, 2026, setting its target at $480.00, while Guggenheim held a Buy rating with a $475.00 target on October 1, 2026. RBC Capital maintained an Outperform rating on September 25, 2026, raising its target to $460.00, and UBS kept a Buy rating on September 9, 2026, lifting its target to $435.00. Overall, the company holds a strong buy consensus recommendation among 23 analysts.

About Natera, Inc.

Headquartered in Austin, Texas, Natera operates as a diagnostics company focused on developing molecular testing services. Its portfolio includes personalized ctDNA blood tests for cancer assessment like Signatera, non-invasive prenatal tests such as Panorama, and various carrier and hereditary screening tools used by medical centers and reference laboratories worldwide.

What to Watch at Natera, Inc.

Investors tracking Natera will look ahead to the company's next earnings report scheduled for November 5, 2026. Future filings will show whether insider buying trends persist as the diagnostics provider continues scaling its molecular testing business.